Abstract

The aim of the study was to examine the prognostic significance of inflammatory biomarkers in patients (pts) with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) undergoing first-line chemotherapy with nab-paclitaxel and gemcitabine (NPG).

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call